Effects of Semaglutide on Muscle Structure and Function in the SLIM LIVER Study
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide is highly effective for decreasing weight. Concomitant loss of muscle mass often accompanies weight loss and may have consequences on muscle function. METHODS: This is a secondary analysis from the SLIM LIVER (Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, ACTG A5371) study, a single-arm study of semaglutide in people with human immunodeficiency virus (HIV, PWH) with metabolic dysfunction-associated steatotic liver diseases (MASLD). Participants received subcutaneous semaglutide for 24 weeks (titrated to 1 mg/week by week 4). Psoas volume and fat fraction were assessed from liver magnetic resonance imaging, and physical function was assessed by 10-time chair rise test and 4 m gait speed. Mean change from baseline to week 24 was estimated with linear regression modeling. RESULTS: Fifty-one PWH were enrolled (muscle measures n = 46). The mean age was 50 years (standard deviation, 11), body mass index was 35.5 kg/m2 (5.6), 43% were women, 33% Black, and 39% Hispanic/Latino. Psoas muscle volume decreased by 9.3% (95% confidence interval [CI]: -13.4 to -5.2; P < .001) over 24 weeks, but psoas muscle fat did not significantly change (-0.42%; 95% CI: -1.00 to .17; P = .16). Chair rise and gait speed showed nonsignificant improvements of 1.27 seconds (95% CI: -2.7 to .10) and 0.05 m/sec (95% CI: -.01 to .10), respectively (both P > .07). The prevalence of slow gait speed (<1 m/sec) decreased from 63% to 46% (P = .029). CONCLUSIONS: In PWH receiving semaglutide for MASLD, despite decreased psoas muscle volume, there was no significant change in physical function, suggesting function was maintained despite significant loss of muscle. CLINICAL TRIALS REGISTRATION: NCT04216589.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The trial, which led to the approval of semaglutide for obesity treatment, revealed that up to 40% of total body weight loss could be attributed to lean body mass reduction, exceeding the approximate 25% commonly seen with standard caloric restriction [2].”
From Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions (2025) · cites this paper as [2]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International physical activity questionnaire: 12-country reliability and validity
CRAIG, C. L., MARSHALL, A. L., SJ??STR??M, M., BAUMAN, A. E., BOOTH, M. L., AINSWORTH, B. E., PRATT, M., EKELUND, U., YNGVE, A., SALLIS, J. F., et al. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000078924.61453.fb · Cited by 21,619
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
Non-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669
Weight loss, exercise, or both and physical function in obese older adults
Villareal, D. T., Chode, S., Parimi, N., Sinacore, D. R., Hilton, T., Armamento-Villareal, R., Napoli, N., Qualls, C., & Shah, K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008234 · Cited by 1,096
Cusi, K., Isaacs, S., Barb, D., Basu, R., Caprio, S., Garvey, W. T., Kashyap, S., Mechanick, J. I., Mouzaki, M., Nadolsky, K., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.010 · Cited by 1,021
Rubino, D. M., Greenway, F. L., Khalid, U., O’Neil, P. M., Rosenstock, J., Sørrig, R., Wadden, T. A., Wizert, A., Garvey, W. T., STEP 8 Investigators, et al. (2022) · JAMA · doi:10.1001/jama.2021.23619 · Cited by 995
Targher, G., Byrne, C. D., & Tilg, H. (2020) · Gut · doi:10.1136/gutjnl-2020-320622 · Cited by 827
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533
Bohannon, R. W., & Glenney, S. S. (2014) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.12158 · Cited by 431
NAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 405
Semaglutide for the treatment of overweight and obesity: A review
Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14863 · Cited by 265
Exercise attenuates the weight-loss-induced reduction in muscle mass in frail obese older adults
FRIMEL, T. N., SINACORE, D. R., & VILLAREAL, D. T. (2008) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31816a85ce · Cited by 230
Jensen, S. B. K., Blond, M. B., Sandsdal, R. M., Olsen, L. M., Juhl, C. R., Lundgren, J. R., Janus, C., Stallknecht, B. M., Holst, J. J., Madsbad, S., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102475 · Cited by 207
Weight loss strategies and the risk of skeletal muscle mass loss
McCarthy, D., & Berg, A. (2021) · Nutrients · doi:10.3390/nu13072473 · Cited by 163
Assessment of Lean Mass and Physical Performance in Sarcopenia
Cawthon, P. M. (2015) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.05.063 · Cited by 138
Santanasto, A. J., Glynn, N. W., Newman, M. A., Taylor, C. A., Brooks, M. M., Goodpaster, B. H., & Newman, A. B. (2011) · Journal of Obesity · doi:10.1155/2011/516576 · Cited by 132
A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
Bikou, A., Dermiki-Gkana, F., Penteris, M., Constantinides, T. K., & Kontogiorgis, C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2343092 · Cited by 97
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., et al. (2022) · Nutrients · doi:10.3390/nu14214673 · Cited by 84
Ebadi, M., Tsien, C. D., Bhanji, R. A., Dunichand‐Hoedl, A. R., Rider, E., Motamedrad, M., Mazurak, V. C., Baracos, V. E., & Montaño‐Loza, A. J. (2022) · Cells · doi:10.3390/cells11071216 · Cited by 79
Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus
Lake, J. E., Overton, T., Naggie, S., Sulkowski, M., Loomba, R. S., Kleiner, D. E., Price, J. C., Chew, K. W., Chung, R. T., & Corey, K. E. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.018 · Cited by 78
Self-citationSchrack, J. A., Simonsick, E. M., & Ferrucci, L. (2013) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e3182644165 · Cited by 71
Tatangelo, T., Muollo, V., Ghiotto, L., Schena, F. F., & Rossi, A. P. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.111902 · Cited by 69
Volpe, S., Lisco, G., Racaniello, D., Fanelli, M., Colaianni, V., Vozza, A., Triggiani, V., Sabbà, C., Tortorella, C., De Pergola, G., et al. (2022) · Nutrients · doi:10.3390/nu14122414 · Cited by 67
Impact of myosteatosis on skeletal muscle volume loss in patients with chronic liver disease
Tachi, Y., Kozuka, A., Hirai, T., Ishizu, Y., Honda, T., Kuzuya, T., Hayashi, K., Ishigami, M., & Goto, H. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14133 · Cited by 55
Eckard, A. R., Wu, Q., Sattar, A., Ansari-Gilani, K., Labbato, D., Foster, T., Fletcher, A. A., Adekunle, R. O., & McComsey, G. A. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00150-5 · Cited by 55
Effects of weight loss and exercise on trunk muscle composition in older women
Ryan, A., & Harduarsingh-Permaul, A. S. (2014) · Clinical Interventions in Aging · doi:10.2147/cia.s56662 · Cited by 50
Yoshimura, E., Kumahara, H., Tobina, T., Matsuda, T., Watabe, K., Matono, S., Ayabe, M., Kiyonaga, A., Anzai, K., Higaki, Y., et al. (2014) · Obesity Facts · doi:10.1159/000358576 · Cited by 48
Metabolic concerns in aging HIV-infected persons: from serum lipid phenotype to fatty liver
Guaraldi, G., Lonardo, A., Maia, L. E. O., & Palella, F. J. (2017) · AIDS · doi:10.1097/qad.0000000000001483 · Cited by 47
Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Klingman, K. L., Vernon, C., Belaunzarán-Zamudio, P. F., Fichtenbaum, C. J., Heath, S. L., Perazzo, H., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-3354 · Cited by 38
Self-citationVogt, L., Steveling, A., Meffert, P. J., Kromrey, M., Keßler, R., Hosten, N., Krüger, J., Gärtner, S., Aghdassi, A. A., Mayerle, J. V., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0153595 · Cited by 31
Differences in Muscle Quantity and Quality by HIV Serostatus and Sex
Erlandson, K. M., Langan, S. J., Lake, J. E., Sun, J., Sharma, A., Adrian, S., Scherzinger, A. L., Palella, F. J., Kingsley, L., Gange, S. J., et al. (2022) · The Journal of Frailty & Aging · doi:10.14283/jfa.2022.11 · Cited by 23
Self-citationPatzelt, L., Junker, D., Syväri, J., Burian, E., Wu, M., Prokopchuk, O., Nitsche, U., Makowski, M. R., Braren, R., Herzig, S., et al. (2021) · Cancers · doi:10.3390/cancers13174433 · Cited by 18
Mitsui, Y., Sadahira, T., Araki, M., Maruyama, Y., Wada, K., Tanimoto, R., Kobayashi, Y., Watanabe, M., Watanabe, T., & Nasu, Y. (2018) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyy166 · Cited by 14
Ahmad, E., Arsenyadis, F., Almaqhawi, A., Barker, M., Jobanputra, R., Sargeant, J. A., Webb, D. R., Yates, T. E., & Davies, M. J. (2023) · Diabetic Medicine · doi:10.1111/dme.15083 · Cited by 14
Sanaka, K., Hashimoto, K., Kurosawa, D., Murakami, E., Ozawa, H., Takahashi, K., Onoki, T., & Aizawa, T. (2022) · Gait & Posture · doi:10.1016/j.gaitpost.2022.02.018 · Cited by 8
Research works printed but not linked: 1
- Eckard, 2024, Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial, Lancet Diabetes Endocrinol, S2213–8587, 00150-5
Cited by
Karakasis, P., Patoulias, D., Fragakis, N., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2024.156113 · Cited by 242
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
“In NCT04216589, conducted in patients with NAFLD and HIV, semaglutide led to reductions in steatosis ( − 4.2%), HbA1c, weight ( − 7.8 kg), BMI ( − 2.8 units), and waist circumference ( − 6.7 cm) [75].”
InfluentialKunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 44
Scheen, A. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101681 · Cited by 30
Metadata
- Authors
- Ditzenberger, G. L., Lake, J. E., Kitch, D. W., Kantor, A., Muthupillai, R., Moser, C., Belaunzaran-Zamudio, P. F., Brown, T. T., Corey, K., Landay, A. L., Avihingsanon, A., Sattler, F. R., & Erlandson, K. M.
- Affiliations
- University of Colorado Anschutz (US)
- The University of Texas Health Science Center at Houston (US)
- Harvard University (US)
- Texas A&M University (US)
- National Institute of Allergy and Infectious Diseases (Contractor) , Rockville, Maryland ,
- Johns Hopkins University (US)
- The University of Texas Medical Branch at Galveston (US)
- Thai Red Cross Society (TH)
- University of Southern California (US)
- Corresponding author
- Ditzenberger, Grace L
- Erlandson, Kristine M
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2024-07-24
- Volume
- 80
- Issue
- 2
- Pages
- 389-396
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC11848261
- OpenAlex
- W4400967991
- Cited by
- 44
- References
- 40
- Citations by year
- 2026: 24 · 2025: 15 · 2024: 5
- FWCI
- 23.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NIAID (UM1 AI068634, UM1 AI068636, UM1 AI106701)
- NIH
- McGovern School of Medicine at UTHealth (T32 AI150547, K24 AI120834)
- National Institute on Aging (K24 AG082527)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- semaglutide, HIV, non-alcoholic fatty liver disease, muscle mass loss, muscle fat fraction, physical function, walking speed, chair stand test, weight loss, GLP-1 receptor agonists
- MeSH terms
- Semaglutide, Adult, Glucagon-Like Peptides, Fatty Liver, Female, Humans, Liver, Magnetic Resonance Imaging, Male, Middle Aged, Weight Loss, HIV Infections, Psoas Muscles, Muscle, Skeletal, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.